Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family
H. Michael Shepard, … , Cathleen M. Brdlik, Hans Schreiber
H. Michael Shepard, … , Cathleen M. Brdlik, Hans Schreiber
Published November 3, 2008
Citation Information: J Clin Invest. 2008;118(11):3574-3581. https://doi.org/10.1172/JCI36049.
View: Text | PDF
Review Series

Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family

  • Text
  • PDF
Abstract

The human EGFR (HER) family is essential for communication between many epithelial cancer cell types and the tumor microenvironment. Therapeutics targeting the HER family have demonstrated clinical success in the treatment of diverse epithelial cancers. Here we propose that the success of HER family–targeted monoclonal antibodies in cancer results from their ability to interfere with HER family consolidation of signals initiated by a multitude of other receptor systems. Ligand/receptor systems that initiate these signals include cytokine receptors, chemokine receptors, TLRs, GPCRs, and integrins. We further extrapolate that improvements in cancer therapeutics targeting the HER family are likely to incorporate mechanisms that block or reverse stromal support of malignant progression by isolating the HER family from autocrine and stromal influences.

Authors

H. Michael Shepard, Cathleen M. Brdlik, Hans Schreiber

×

Figure 2

Members of the HER family consolidate signals from cancer and stromal cells.

Options: View larger image (or click on image) Download as PowerPoint
Members of the HER family consolidate signals from cancer and stromal ce...
There are a multitude of signaling molecules secreted by cancer cells and the tumor-associated stromal cells (e.g., inflammatory cells, endothelial cells, and fibroblasts) that modulate HER family function. Activation of GPCRs (e.g., by chemokines), TLRs (e.g., by HSP70), and cytokine receptors (e.g., by TGF-β) can lead to transactivation of HER family members, as shown here for EGFR. These receptors link the HER family to innate and adaptive immunity, including immunosurveillance, which is important for protection against incipient tumor progression (38). Although not shown here, activation of other receptors, e.g., receptors for WNT (116) and integrins, can also lead to transactivation (117). Although only transactivation of EGFR is shown in this figure, other HER family members are also subject to transactivation by the same diversity of ligand/receptor systems. Transactivation is mediated primarily by metalloproteinase activation (ADAMs and MMPs) of precursor HER ligands and also by intracellular signal transducers (such as Src family kinases [SFKs]), which can amplify this effect. This creates a situation in which the HER family acts as a conduit for diverse signaling systems. Most of the receptor systems described here are present in both nonmalignant stromal cells and cancer cells.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts